(CMS–10531) Transcatheter
Mitral Valve Repair (TMVR) National Coverage Decision (NCD)
Revision of a currently approved collection
No
Regular
09/24/2021
Requested
Previously Approved
36 Months From Approved
12/31/2021
34,596
15,588
16,001
5,456
0
0
Decision Memorandum CAG#-00438N
entitled Transcatheter Mitral Valve Repair (TMVR) for Degenerative
Mitral Regurgitation was published August 7, 2014. In this
decision, CMS determined that it the evidence is sufficient to
cover TMVR under Coverage with Evidence Development for Medicare
beneficiaries under certain conditions only when the provider is
participating in and patients are enrolled in a qualifying clinical
studies meeting certain requirements. Consistent with section 1142
of the Social Security Act, the Agency for Healthcare Research and
Quality (AHRQ) supports clinical research studies that the CMS
determines meet specified standards and address the specified
research questions.
The increase in the annual
number of TEER procedures performed is representative of the
evolving field and providers growing more comfortable with
performing and providing the services. The respondents increased
from 3,897 to 8,649. The burden hours increased from 4,092 to
12,974 for TEER. The total burden hour increased from 5,456 to
16,001.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.